逍遥散加减方对慢性疲劳综合征(CFS)患者情绪状态及淋巴细胞凋亡的影响

目的研究CFS与患者情绪状态及外周血淋巴细胞凋亡的关系。方法采用治疗前后对照研究。结果CFS组治疗前情绪各状态明显高于健康对照组(P<0.05);逍遥散加减方治疗后CFS患者各种情绪及疲劳因子明显低于治疗前(P<0.01);CFS组治疗前淋巴细胞凋亡率明显高于健康对照组(P<0.01);逍遥散加减方治疗后CFS患者外周血淋巴细胞凋亡率明显低于治疗前(P<0.05);CFS组治疗前淋巴细胞中bcl-2表达明显高于健康对照组(P<0.01);逍遥散加减方治疗后CFS患者外周血淋巴细胞中bcl-2表达明显低于治疗前(P<0.05)。结论CFS的发病过程存在着细胞凋亡,而且中药有调节作用。     

救急行军散中雄黄的含量测定

目的:建立救急行军散中雄黄的含量测定方法.方法:采用分光光度法对散剂中雄黄所含有的砷进行定量分析.结果:砷的线性范围为2.5～22.5μg,r=0.9995,平均回收率为100.1%,RSD为1.0%.结论:方法简便可行、重线性好,适用于该制剂的质量控制.     

复方逍遥合剂中黄芩苷的薄层扫描测定

建立了薄层扫描法测定复方逍遥合剂中黄芩苷含量,并采用TLC法对黄柏、白芍、柴胡、贝母等成分进行鉴别.黄芩苷点样量在0.15～0.75μg范围内线性关系良好(r=0.9987),平均回收率99.2%(RSD 1.5%).     

敛溃散抗溃疡病机制分析和急性毒性试验

目的探讨敛溃散抗溃疡病机制并初步评价其安全性.方法抗酸作用采用酸碱滴定法,抑制胃蛋白酶活性和胃酸分泌作用分别采用Mett玻管法和大鼠插管法,镇痛作用采用小鼠扭体法,并观察敛溃散对出、凝血时间,以及胃肠蠕动和中枢神经系统的影响.结果 1g敛溃散能中和7.14mmol盐酸,显著降低大鼠胃液总酸度和胃蛋白酶活性;减少醋酸引起的小鼠扭体次数,缩短兔股动脉出血时间而不影响凝血时间,延长异戊巴比妥钠对小鼠的催眠时间.对大鼠胃酸分泌和小鼠胃肠蠕动未见明显影响.小鼠对敛溃散的最大耐受倍数为171倍.结论临床使用敛溃散是安全的,抗酸、抑制胃蛋白酶、局部止血和黏膜保护以及镇痛等作用是其抗溃疡病的主要机制.     

逍遥散方剂中水溶性多糖的研究

目的研究逍遥散方剂中活性成分--水溶性多糖.方法以Sephadex G-150凝胶柱分离粗多糖,凝胶过滤法测定相对分子质量,经红外扫描、酸水解、高碘酸氧化和Smith降解确定组成和初级结构.结果两种水溶性多糖:PXB-1相对分子质量为7.9×103,由葡萄糖(94.7%)和一未知成分(5.3%)组成,PXB-2相对分子质量为2.5×103,由葡萄糖(28.1%)、半乳糖(42.9%)、甘露糖(29.0%)组成.两者均为α(1→2)型糖苷键链接.结论PXB-1和PXB-2首次从逍遥散方剂中分得,并首次报道了其组成及初级结构.     

双歧异黄酮奶粉抗氧化作用研究

目的:研究双歧异黄酮奶粉的抗氧化作用.方法:小鼠每4d注射阿霉素(ADR)5mg/kg,连续4次,制备小鼠高过氧化模型,同时实验组予双歧异黄酮奶粉灌胃(8.38,16.67,50.00g/kg),对照组予普通奶粉,测定小鼠的抗氧化能力.结果:双歧异黄酮奶粉能明显提高小鼠超氧化物歧化酶(S0D)活性,降低脂质过氧化物(LP0)含量.结论:双歧异黄酮奶粉具有抗氧化作用.     

Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder (青黄散) in Patients with Myelodysplastic Syndrome

Objective: To investigate the relation of blood arsenic concentration(BAC) with clinical effect and safety of arsenic-containing Qinghuang Powder(青黄散, QHP) in patients with myelodysplastic syndrome(MDS). Methods: Totally 163 patients with MDS were orally treated with QHP for 2 courses of treatment, 3 months as 1 course. The BACs of patients were detected by atomic fluorescence spectrophotometry at 1, 3, and 6 months during the treatment, and the effective rate, hematological improvement and safety in patients after treatment with QHP were analyzed. Results: After 2 courses of treatment, the total effective rate was 89.6%(146/163), with 31.3%(51/163) of hematological improvement and 58.3%(95/163) of stable disease. The hemoglobin increased from 73.48±19.30 g/L to 80.39±26.56 g/L(P0.05), the absolute neutrophil count increased from 0.81±0.48×10~9/L to 1.08±0.62×10~9/L(P0.05), and no significant changes were observed in platelet counts(P0.05). Among 46 patients previously depended on blood transfusion, 28.3%(13/46) completely got rid of blood transfusion and 21.7%(10/46) reduced the volume of blood transfusion by more than 50% after treatment. The BACs were significantly increased in patients treated for 1 month with 32.17±18.04 μg/L(P0.05), 3 months with 33.56±15.28 μg/L(P0.05), and 6 months with 36.78±11.92 μg/L(P0.05), respectively, as compared with those before treatment(4.08±2.11 μg/L). There were no significant differences of BACs among the patients treated for 1, 3 and 6 months(P0.05). The adverse reactions of digestive tract during the treatment were mild abdominal pain and diarrhea in 14 cases(8.6%), and no patients discontinued the treatment. The BACs of patients with gastrointestinal adverse reactions were significantly lower than those without gastrointestinal adverse reactions(22.39±10.38 vs. 37.89±11.84, μg/L, P0.05). The BACs of patients with clinical effect were significantly higher than those failed to treatment(40.41±11.69 vs. 23.84±12.03, μg/L, P0.05). Conclusion: QHP was effective and safe in the treatment of patients with MDS and the effect was associated with BACs of patients.     

七味白术散治疗小儿腹泻研究概况

腹泻是小儿消化系统常见疾病,严重影响小儿身体健康。七味白术散出自《小儿药证直诀》,为治疗小儿腹泻良方。文章将该方近10余年来的研究情况进行归纳总结,分别从临床研究、实验研究及药理研究等方面进行全面阐述,以便更好地指导临床,并为临床应用提供更多的理论依据。     

清胃散加味治疗复发性口腔溃疡53例

目的:观察清胃散加味治疗复发性口腔溃疡的临床疗效.方法:选取复发性口腔溃疡患者53例,均给予清胃散加味治疗.结果:53例患者中,治愈49例,好转3例,未愈1例,有效率为98.11％.结论:清胃散加味治疗复发性口腔溃疡疗效显著.     

Theoretical and Experimental Evaluation of Flow Pattern of Pharmaceutical Powder Blends Discharged From Intermediate Bulk Containers (IBCs)

The purpose of this study is to assess the prevalence of funnel flow pattern for common pharmaceutical powder blends, upon discharging from modern intermediate bulk containers (IBCs) in drug product manufacturing. The estimation was built upon Jenike’s original radial stress field theory. It was modified to account for the stress-dependence of wall friction angle commonly observed in pharmaceutical powders. A total of 260 flow pattern estimations, based on 20 real-life IBCs and 13 investigational powder blends, were made. The estimated results showed that the mass flow pattern is present in less than 5% of all cases. Funnel flow pattern is clearly prevalent among pharmaceutical powder blends. The prevalence of funnel flow stems from several factors: 1) relatively shallow hopper section shared by all IBCs, 2) the common transition-type geometry, leading to even shallower hopper inclination at the edge of the hopper section, and 3) relatively high wall friction angles resulting from low wall normal stresses. This conclusion was verified through at-scale experiments, by discharging multiple pharmaceutical powder blends from a representative IBC. In general, our study suggests that, unless the powder wall friction can be substantially reduced, pharmaceutical powders are likely to discharge under funnel flow from modern IBCs.